After losing the top spot in March to Johnson & Johnson’s immunology drug Tremfya, AbbVie’s rival med Skyrizi is back as the drug with the highest level of ad spending.
AbbVie shelled out $46.8 million on Skyrizi ads in April, up $4.7 million month over month, putting the drug comfortably ahead of Tremfya.
J&J’s med landed in second place, with spending down a sizable $10.6 million, according to data shared with Fierce Pharma Marketing by analysts at iSpot.tv.
AbbVie’s other major immunology med, Rinvoq, held onto third place in April—but it was a close race with J&J, with Rinvoq’s ad spending just $200,000 behind Tremfya.
Eli Lilly nudged up spending on its obesity drug Zepbound by $1.5 million, pushing the med into fourth place, up one spot from March.
In fifth place, and up two spots, was Sanofi and Regeneron’s immunology megablockbuster Dupixent, with the majority of its $20.4 million spend last month going toward ads tied to its eczema indication.
Johnson & Johnson appeared again on the list with its atypical antipsychotic Caplyta, which fell two spots to sixth place as spending dropped from $23.4 million in March to $20.2 million in April.
Lundbeck and Otsuka’s depression drug Rexulti landed in seventh place, while Eli Lilly and Boehringer Ingelheim’s diabetes and kidney disease med Jardiance came in eighth, down from sixth in March as spending fell by $8.2 million.
The final two spots went to AbbVie’s atypical antipsychotic Vraylar—which was absent from the rankings in March and returned in ninth place—and Neurocrine’s Ingrezza, which is approved for tardive dyskinesia and chorea associated with Huntington’s disease.
Check out April’s biggest ad spenders below, based on data compiled by analysts at iSpot.tv.
1. Skyrizi
Movement: Up one spot
What is it? AbbVie’s immunology drug
Est. national linear TV ad spend: $46.8 million (up from $42.1 million in March)
- UC/Crohn’s disease: $21.4 million
- Psoriasis: $22.9 million
- Psoriatic arthritis: $2.5 million
Top TV network by spend share of voice (SOV): ABC (23.18%)
Top TV program by spend SOV: SportsCenter (2.19%)
Number of spots: Five (one psoriatic arthritis, two psoriasis, two UC/Crohn’s disease)
Biggest-ticket ad: “I'm All In: Swimming Pool” (est. $21.4 million)
2. Tremfya
Movement: Down one spot
What is it? Johnson & Johnson’s immunology drug
Est. national linear TV ad spend: $39.7 million (down from $50.3 million in March)
- UC/Crohn’s disease: $25.8 million
- Psoriasis: $1.2 million
- Psoriatic arthritis: $12.8 million
Top TV network by spend SOV: ABC (19.76%)
Top TV program by spend SOV: Men’s college basketball (7.60%)
Number of spots: Eight (three psoriatic arthritis, one psoriasis, four UC/Crohn’s disease)
Biggest-ticket ad: “Relentless Weed” (est. $12.7 million)
3. Rinvoq
Movement: No movement
What is it? AbbVie’s JAK inhibitor immunology drug
Est. national linear TV ad spend: $39.5 million (up from $36.3 million in March)
- Arthritis: $10 million
- Eczema: $11.2 million
- UC/Crohn’s disease: $18.3 million
Top TV network by spend SOV: ABC (27.52%)
Top TV program by spend SOV: Today (4.50%)
Number of spots: Seven (two arthritis, two UC/Crohn’s disease, three eczema)
Biggest-ticket ad: “Classic Car, Tennis and Fire Station” (est. $18.2 million)
4. Zepbound
Movement: Up one spot
What is it? Eli Lilly’s obesity drug
Est. national linear TV ad spend: $24.4 million (up from $22.9 million in March)
Top TV network by spend SOV: CBS (20.16%)
Top TV program by spend SOV: Men’s college basketball (30.23%)
Number of spots: Seven
Biggest-ticket ad: “Watch This: Head-to-Head” (est. $13.1 million)
5. Dupixent
Movement: Up two spots
What is it? Sanofi and Regeneron’s immunology drug
Est. national linear TV ad spend: $20.4 million (up from $19.6 million in March)
- Eczema: $13.7 million
- Asthma: $6.7 million
- Gastrointestinal: $36.5K
Top TV network by spend SOV: ABC (32.31%)
Top TV program by spend SOV: Men’s college basketball (6.57%)
Number of spots: Eight (three asthma, four eczema, one gastrointestinal)
Biggest-ticket ad: “Feel the Heal” (est. $8.2 million)
6. Caplyta
Movement: Down two spots
What is it? Johnson & Johnson’s atypical antipsychotic drug
Est. national linear TV ad spend: $20.2 million (down from $23.4 million in March)
Top TV network by spend SOV: ABC (19.61%)
Top TV program by spend SOV: 2026 NFL Draft (4.91%)
Number of spots: Three
Biggest-ticket ad: “Let in the Lyte: More Relief” (est. $7.5 million)
7. Rexulti
Movement: Up one spot
What is it? Lundbeck and Otsuka’s neurology drug
Est. national linear TV ad spend: $17.8 million (up from $16.5 million in March)
Top TV network by spend SOV: CBS (16.32%)
Top TV program by spend SOV: NCIS (4.32%)
Number of spots: Two
Biggest-ticket ad: “Progress” (est. $17.8 million)
8. Jardiance
Movement: Down two spots
What is it? Eli Lilly and Boehringer Ingelheim’s diabetes and kidney disease drug
Est. national linear TV ad spend: $12.6 million (down from $20.8 million in March)
- CKD: $3 million
- Diabetes: $9.7 million
Top TV network by spend SOV: ABC (20.55%)
Top TV program by spend SOV: ABC World News Tonight With David Muir (4.64%)
Number of spots: Two (one CKD, one diabetes)
Biggest-ticket ad: “Behind the Scenes” (est. $9.7 million)
9. Vraylar
Movement: Not listed last month
What is it? AbbVie’s atypical antipsychotic
Est. national linear TV ad spend: $12.1 million (up from $10.5 million in March)
- Bipolar: $4.5 million
- Depression: $7.6 million
Top TV network by spend SOV: ABC (9.68%)
Top TV program by spend SOV: NBA (6.54%)
Number of spots: Three (two depression, one bipolar)
Biggest-ticket ad: “Jane’s Head” (est. $7.5 million)
10. Ingrezza
Movement: Not listed last month
What is it? Neurocrine’s tardive dyskinesia and chorea associated with Huntington’s disease drug
Est. national linear TV ad spend: $11 million (up from $8 million in March)
Top TV network by spend SOV: CBS (19.09%)
Top TV program by spend SOV: ABC World News Tonight With David Muir (7.71%)
Number of spots: Two
Biggest-ticket ad: “Flowing Stories” (est. $11 million)